Global Anti-Obesity Prescription Market 2020-2029(Includes Business Impact of COVID-19)

  • TBI855489
  • May 03, 2019
  • Global
  • 98 pages
  • QY Market Research

"The ongoing Coronavirus (COVID-19) pandemic is re-shaping everything from global economies to product categories, pricing, and stock availability to the consumer behavior. The final report is updated to address the impact of COVID-19 on the Anti-Obesity Prescription market. Trusted Business Insights is tracking mining/oil and gas, transportation, employment services, travel arrangements, and the leisure and hospitality sector closely as they are likely to be the hardest-hit sectors. Utilities, local pharma, diagnostics, consumer goods and durables, agro chem and fertilizers, and telecommunications are the sectors that will be weathering the COVID-19 storm and most likely come out relatively unscathed. Interdependencies of sectors are factored in our research report on the Anti-Obesity Prescription market." Obesity is a public health problem. Obesity is a genetic and chronic metabolic disease involving accumulation of excessive or abnormal fat in the body. It contributes to risk of chronic conditions such as cancer, hypertension, cardiovascular diseases, diabetics, obstructive sleep apnea, ventilatory failure, renal failure and asthma. According to a World Health Organization (WHO) report published in 2014, around 3.4 million adults in the world die each year due to obesity related issues. Increasing prevalence of obesity among children and adults is posing a threat and developing nations. Effective intervention strategies such as increased physical activity, behavioral and dietary changes are commonly used to control and prevent obesity. Obesity has a major impact on population longevity and health related expense. There is increased use of anti-obesity prescription due to increasing obesity endemic. Sedentary lifestyle and junk food habits, increasing healthcare expenditure and rise in aging population are some of the key factors driving the growth for global anti-obesity prescription market. In addition, increasing healthcare awareness is also fuelling the growth of the global anti-obesity prescription market. However, side effects of anti-obesity drugs, high drug development cost and strict regulatory framework are some of the major factors restraining the growth for the global anti-obesity prescription market. The global Anti-Obesity Prescription market is valued at xx million US$ in 2020 is expected to reach xx million US$ by the end of 2029, growing at a CAGR of xx% during 2020-2029. This report focuses on Anti-Obesity Prescription volume and value at global level, regional level and company level. From a global perspective, this report represents overall Anti-Obesity Prescription market size by analyzing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and Japan. At company level, this report focuses on the production capacity, ex-factory price, revenue and market share for each manufacturer covered in this report. The following manufacturers are covered:

  • Zydus Cadila
  • Akrimax Pharmaceuticals
  • Zealand Pharma
  • Arrowhead Research
  • Arena Pharmaceuticals
  • Compellis Pharmaceuticals
  • Yungjin Pharm
  • Alpex Pharma
  • Bridge BioResearch
Segment by Regions
  • North America
  • Europe
  • China
  • Japan
Segment by Type
  • Bupropion and Naltrexone
  • Orlistat
  • Lorcaserin
  • Phentermine and Topiramate
  • Liraglutide
Segment by Application
  • Hospital Pharmacies
  • Retail Pharmacies
  • E-Commerce
In Aug 2020, Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Hanmi Pharmaceutical today announced that the companies have entered into an exclusive licensing agreement for the development, manufacture and commercialization of efinopegdutide (formerly HM12525A),Hanmi’s investigational once-weekly glucagon-like peptide-1 (GLP-1)/glucagon receptor dual agonist, for the treatment of nonalcoholic steatohepatitis (NASH). Under the agreement, Merck will be granted an exclusive license to develop, manufacture and commercializeefinopegdutidein the United States and globally. Hanmi will receive an upfront payment of $10 million and is eligible to receive milestone payments up to $860 million associated with the development, regulatory approval and commercialization of efinopegdutide,as well as double-digit royalties on sales of approved product. Hanmi retains an option to commercialize efinopegdutide in Korea. Efinopegdutide is a GLP-1/glucagon receptor dual agonist, which activates both the GLP-1 and glucagon receptors. The safety and efficacy of efinopegdutide has previously been evaluated in multiple Phase 1 and Phase 2 clinical trials, including for the treatment of severely obese individuals with and without type 2 diabetes mellitus.

Table of Contents

Executive Summary
1 Anti-Obesity Prescription Market Overview
    1.1 Product Overview and Scope of Anti-Obesity Prescription
    1.2 Anti-Obesity Prescription Segment by Type
        1.2.1 Global Anti-Obesity Prescription Production Growth Rate Comparison by Type (2014-2025)
        1.2.2 Bupropion and Naltrexone
        1.2.3 Orlistat
        1.2.4 Lorcaserin
        1.2.5 Phentermine and Topiramate
        1.2.6 Liraglutide
    1.3 Anti-Obesity Prescription Segment by Application
        1.3.1 Anti-Obesity Prescription Consumption Comparison by Application (2014-2025)
        1.3.2 Hospital Pharmacies
        1.3.3 Retail Pharmacies
        1.3.4 E-Commerce
    1.4 Global Anti-Obesity Prescription Market by Region
        1.4.1 Global Anti-Obesity Prescription Market Size Region
        1.4.2 North America Status and Prospect (2014-2025)
        1.4.3 Europe Status and Prospect (2014-2025)
        1.4.4 China Status and Prospect (2014-2025)
        1.4.5 Japan Status and Prospect (2014-2025)
    1.5 Global Anti-Obesity Prescription Market Size
        1.5.1 Global Anti-Obesity Prescription Revenue (2014-2025)
        1.5.2 Global Anti-Obesity Prescription Production (2014-2025)

2 Global Anti-Obesity Prescription Market Competition by Manufacturers
    2.1 Global Anti-Obesity Prescription Production Market Share by Manufacturers (2014-2019)
    2.2 Global Anti-Obesity Prescription Revenue Share by Manufacturers (2014-2019)
    2.3 Global Anti-Obesity Prescription Average Price by Manufacturers (2014-2019)
    2.4 Manufacturers Anti-Obesity Prescription Production Sites, Area Served, Product Types
    2.5 Anti-Obesity Prescription Market Competitive Situation and Trends
        2.5.1 Anti-Obesity Prescription Market Concentration Rate
        2.5.2 Anti-Obesity Prescription Market Share of Top 3 and Top 5 Manufacturers
        2.5.3 Mergers & Acquisitions, Expansion

3 Global Anti-Obesity Prescription Production Market Share by Regions
    3.1 Global Anti-Obesity Prescription Production Market Share by Regions
    3.2 Global Anti-Obesity Prescription Revenue Market Share by Regions (2014-2019)
    3.3 Global Anti-Obesity Prescription Production, Revenue, Price and Gross Margin (2014-2019)
    3.4 North America Anti-Obesity Prescription Production
        3.4.1 North America Anti-Obesity Prescription Production Growth Rate (2014-2019)
| 

Request a sample

Fill below form to request a sample


Please fill this form to enquire before buying


You can request for discount regarding the report by using below form